Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370449 | 0.83 | PTGDR2 (0.68) | PTGDR2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1370018 | 0.83 | PTGDR2 (0.72) | PTGDR2KDM4E | |
| SCHEMBL27842534 | 0.78 | KDM4E (0.53) | PTGDR2KDM4EKCNQ3KCNQ2KCNE1 | |
| SCHEMBL1369395 | 0.77 | PTGDR2 (0.57) | PTGDR2KDM4EKCNQ3KCNQ2KCNE1 | |
| SCHEMBL12190102 | 0.77 | KDM4E (0.72) | PTGDR2KDM4EKCNQ3KCNQ2KCNE1 | |
| SCHEMBL1369034 | 0.76 | PTGDR2 (0.52) | PTGDR2MEN1KMT2ANPC1MAPT | |
| SCHEMBL1366570 | 0.76 | PARP1 (0.38) | — | |
| SCHEMBL1369203 | 0.75 | RAB9A (0.51) | PTGDR2MEN1KMT2ANPC1MAPT | |
| SCHEMBL1370613 | 0.75 | PTGDR2 (0.57) | PTGDR2RAB9A | |
| SCHEMBL1367124 | 0.75 | L3MBTL1 (0.38) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2377851-A1 | ISOQUINOLINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | PTGDR2 189/4885KDM4E 4115/4885KCNQ3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.